Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)
Journal
Targeted oncology
Journal Volume
19
Journal Issue
1
Date Issued
2024-01
Author(s)
Wang, Hung-Ming
Yang, Muh-Hwa
Chen, Tein-Hua
Lien, Ming-Yu
Lin, Jin-Ching
Lu, Wei-Chen
Lu, Hsueh-Ju
Huang, Tai-Lin
Yen, Chia-Jui
Wu, Shang-Yin
Wang, Hui-Ching
Hsieh, Meng-Che
Abstract
Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although immune checkpoint inhibitors (ICIs) are now considered as first-line treatment, not all patients are suitable for ICIs.
SDGs
Type
journal article